Pharmacogenetics in Oral Antithrombotic Therapy

Clinics in Laboratory Medicine

Volumn 36, Issue 3, 2016, Pages 461-472

  Maier, Cheryl L ^a   Duncan, Alexander ^a   Hill, Charles E ^a  

^a EMORY UNIVERSITY HOSPITAL   (United States)

Author keywords

Anticoagulant; Antiplatelet; Antithrombotic; Personalized medicine; Pharmacogenetics; Pharmacogenomics

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; CLOPIDOGREL; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DABIGATRAN; DABIGATRAN ETEXILATE; EDOXABAN; MULTIDRUG RESISTANCE PROTEIN 1; PLACEBO; PRASUGREL; PURINERGIC P2Y12 RECEPTOR; RIVAROXABAN; TICAGRELOR; WARFARIN; FIBRINOLYTIC AGENT; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; ATRIAL FIBRILLATION; BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; DEEP VEIN THROMBOSIS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG METABOLISM; EMBOLISM; GENETIC ASSOCIATION; GENETIC SCREENING; GENETIC VARIATION; HUMAN; MAXIMUM PLASMA CONCENTRATION; PERSONALIZED MEDICINE; PHARMACODYNAMICS; PHARMACOGENETICS; PHARMACOGENOMICS; PLATELET REACTIVITY; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOEMBOLISM; THROMBOSIS; VENOUS THROMBOEMBOLISM; ANALOGS AND DERIVATIVES; GENETIC POLYMORPHISM; GENOTYPE; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; FIBRINOLYTIC AGENTS; GENOTYPE; HUMANS; POLYMORPHISM, GENETIC; PRECISION MEDICINE; TICLOPIDINE; WARFARIN;

EID: 84989912168     PISSN: 02722712     EISSN: 15579832     Source Type: Journal    
DOI: 10.1016/j.cll.2016.05.002     Document Type: Review

References (70)

1. 1 Valdes, R., Al-Ghoul, M., Fundamentals of pharmacology and applications in pharmacogenetics. Clin Lab Med 28:4 (2008), 485–497.
2. 2 Weinshilboum, R., Inheritance and drug response. N Engl J Med 348 (2003), 529–537.
3. 3 Pengo, V., Pegoraro, C., Cucchini, U., et al. Worldwide management of oral anticoagulant therapy: the ISAM study. J Thromb Thrombolysis 21 (2006), 73–77.
4. 4 Rettie, A.E., Korzekwa, K.R., Kunze, K.L., et al. Hydroxylation of warfarin by human cDNAexpressed cytochrome P450: a role for P4502C9 in the etiology of warfarin drug interactions. Chem Res Toxicol 5:1 (1992), 54–59.
5. 5 Aithal, G.P., Day, C.P., Kesteven, P.J., et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353 (1999), 717–719.
6. 6 Furuya, H., Fernandez-Salguero, P., Gregory, W., et al. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogenetics 5 (1995), 389–392.
7. 7 Lindh, J.D., Holm, L., Andersson, M.L., et al. Influence of CYP2C9 genotype on warfarin dose requirements- a systematic review and meta-analysis. Eur J Clin Pharmacol 65 (2009), 365–375.
8. 8 Rost, S., Fregin, A., Ivaskevicius, V., et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427 (2004), 537–541.
9. 9 Rieder, M.J., Reiner, A.P., Gage, B.F., et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med, 352, 2005, 2285.
10. 10 Cooper, G.M., Johnson, J.A., Langaee, T.Y., et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 112 (2008), 1022–1027.
11. 11 Takeuchi, F., McGinnis, R., Bourgeois, S., et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principle genetic determinants of warfrain dose. PLoS Genet, 5, 2009, e1000433.
12. 12 Limdi, N.A., Brown, T.M., Yan, Q., et al. Race influences warfarin dose changes associated with genetic factors. Blood 126:4 (2015), 539–545.
13. 13 Klein, T.E., Altman, R.B., Eriksson, N., et al. Estimation of the warfarin dose with clinical and pharmacogenomic data. N Engl J Med 360 (2009), 753–764.
14. 14 Li, X., Yang, J., Wang, X., et al. Clinical benefits of pharmacogenetic algorithm-based warfarin dosing: meta-analysis of randomized controlled trials. Thromb Res 135:4 (2015), 621–629.
15. 15 Ansell, J., Hirsh, J., Hylek, E., et al. Pharmacology and management of the vitamin K anatagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest, 133, 2008, 160S.
16. 16 Fuster, V., Bhatt, D.L., Califf, R.M., et al. Guided antithrombotic therapy: current status and future research direction. Circulation 126 (2012), 1645–1662.
17. 17 Shulman, S., Kearon, C., Kakkar, A.K., et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361:24 (2009), 2342–2352.
18. 18 Patel, M.R., Mahaffey, K.W., Garg, J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:10 (2001), 883–891.
19. 19 Eriksson, B.I., Smith, H., Yasothan, U., et al. Dabigatran etexilate. Nat Rev Drug Discov 7:7 (2008), 557–558.
20. 20 Laizure, S.C., Parker, R.B., Herring, V.L., et al. Identification of carboxylesterase-dependent dabigatran etexilate hydrolysis. Drug Metab Dispos 42:2 (2014), 201–206.
21. 21 Blech, S., Ebner, T., Ludwig-Schwellinger, E., et al. The metabolism and disposition of the oral direct thrombin inhibitor dabigatran in humans. Drug Metab Dispos 36 (2008), 386–399.
22. 22 Pare, G., Eriksson, N., Lehr, T., et al. Genetic determinants of dabigatran plasma levels and their relation to bleeding. Circulation 127:13 (2013), 1404–1412.
23. 23 Di Nisio, M., Middeldorp, S., Buller, H.R., Direct thrombin inhibitors. N Engl J Med 353:10 (2005), 1028–1040.
24. 24 Ishiguro, N., Kishimoto, W., Volz, A., et al. Impact of endogenous esterace activity on in vitro p-glycoprotein profiling of dabigatran etexilate in Caco-2 monolayuers. Drug Metab Dispos 42 (2014), 250–256.
25. 25 Hartter, S., Koenen-Bergmann, M., Sharma, A., et al. Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin. Br J Clin Pharmacol 74 (2012), 490–500.
26. 26 New oral anticoagulant drugs dabigatran etexilate and rivaroxaban: influence of genetic factors in healthy volunteers. Available at: https://clinicaltrials.gov/ct2/show/NCT01627665. Accessed January 1, 2016.
27. 27 Influence of ABCB1 polymorphisms on plasma concentrations of new oral anticoagulants in case of serious adverse events. Available at: https://clinicaltrials.gov/ct2/show/NCT02103101. Accessed January 1, 2016.
28. 28 Granger, C.B., Alexander, J.H., McMurray, J.J.V., et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:11 (2011), 981–992.
29. 29 Mega, J.L., Walker, J.R., Ruff, C.T., et al. Genetics and the clinical response to warfarin and edoxaban: findings from the randomized double-blind ENGAGE AF-TIMI 48 trial. Lancet 385:9984 (2015), 2280–2287.
30. 30 Yousuf, O., Bhatt, D.L., The evolution of antiplatelet therapy in cardiovascular disease. Nat Rev Cardiol 8 (2011), 547–559.
31. 31 Tantry, U.S., Bonello, L., Aradi, D., et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 62 (2013), 2261–2273.
32. 32 Aradi, D., Kirtane, A., Bonello, L., et al. Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. Eur Heart J 36:27 (2015), 1762–1771.
33. 33 Undas, A., Brummel-Ziedins, K.E., Mann, K.G., Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions. Blood 109:6 (2007), 2285–2292.
34. 34 Hankey, G.J., Eikelboom, J.W., Aspirin resistance. Lancet 367:9510 (2006), 606–617.
35. 35 Tantry, U.S., Bliden, K.P., Gurbel, P.A., Overestimation of platelet aspirin resistance detection by thromboelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol 46:9 (2005), 1705–1709.
36. 36 Storelli, F., Youssef, D., Desmeules, J., et al. Pharmacogenomics of oral antithrombotic drugs. Curr Pharm Des 22:13 (2016), 1933–1949.
37. 37 Jneid, H., Anderson, J.L., Wright, R.S., et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/Non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 126:7 (2012), 875–910.
38. 38 Dorsam, R.T., Satya, P., Kunapuli, S.P., Central role of the P2Y12 receptor in platelet activation. J Clin Invest 113:3 (2004), 340–345.
39. 39 Yusuf, S., Zhao, F., Mehta, S.R., et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345:7 (2001), 494–502.
40. 40 Ancrenaz, V., Daali, Y., Fontana, P., et al. Impact of genetic polymorphisms and drug-drug interactions on clopidogrel and prasugrel response variability. Curr Drug Metab 11:8 (2010), 667–677.
41. 41 Angiolillo, D.J., Suryadevara, S., Capranzano, P., et al. Prasugrel: a novel platelet ADP P2Y12 receptor antagonist. A review on its mechanism of action and clinical development. Expert Opin Pharmacother 9 (2008), 2893–2900.
42. 42 Wallentin, L., Varenhorst, C., James, S., et al. Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J 29 (2008), 21–30.
43. 43 Wiviott, S.D., Braunwald, E., McCabe, C.H., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357:20 (2007), 2001–2015.
44. 44 Sangkuhl, K., Klein, E.T., Altman, R.B., Clopidogrel pathway. Pharmacogenet Genomics 20:7 (2010), 463–465.
45. 45 Rehmel, J.L., Eckstein, J.A., Farid, N.A., et al. Interaction of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450. Drug Metab Dispos 34:4 (2006), 600–607.
46. 46 Payne, C.D., Li, Y.G., Small, D.S., et al. Increased active metabolite formation explains the greater platelet inhibtion with prasugrel compared to high-dose clopidogrel. J Cardiovasc Pharmacol 50:5 (2007), 555–562.
47. 47 Hulot, J.S., Bura, A., Villard, E., et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108:7 (2006), 2244–2247.
48. 48 Shuldiner, A.R., O'Connell, J.R., Bliden, K.P., et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302:8 (2009), 849–857.
49. 49 Fontana, P., James, R., Barazer, I., et al. Relationship between paraoxonase-1 activity, its Q192R genetic variant and clopidogrel responsiveness in the ADRIE study. J Thromb Haemost 9:8 (2011), 1664–1666.
50. 50 Hochholzer, W., Trenk, D., Fromm, M.F., et al. Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. J Am Coll Cardiol 55:22 (2010), 2427–2434.
51. 51 Lewis, J.P., Stephens, S.H., Horenstein, R.B., et al. The CYP2C19*17 variant is not independently associated with clopidogrel response. J Thromb Haemost 11:9 (2013), 1640–1646.
52. 52 Scott, S.A., Sangkuhl, K., Stein, C.M., et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther 94 (2013), 317–323.
53. 53 Franken, C.C., Kaiser, A.F., Kruger, J.C., et al. Cytochrome P450 2B6 and 2C9 genotype polymorphism – a possible cause of prasugrel low responsiveness. Thromb Haemost 110 (2013), 131–140.
54. 54 Cuisset, T., Loosveld, M., Morange, P.E., et al. CYP2C19*2 and *17 alleles have a significant impact on platelet response and bleeding risk in patients treated with prasugrel after acute coronary syndrome. JACC Cardiovasc Interv 5 (2012), 1280–1287.
55. 55 Mega, J.L., Close, S.L., Wiviott, S.D., et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet 376:9749 (2010), 1312–1319.
56. 56 Mega, J.L., Close, S.L., Wiviott, S.D., et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmokinetic, pharmacodynamic, and clinical outcomes. Circulation 119:19 (2009), 2553–2560.
57. 57 Taubert, D., von Beckerath, N., Grimberg, G., et al. Impact of p-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther 80:5 (2006), 486–501.
58. 58 Price, M.J., Murray, S.S., Angiolillo, D.J., et al. Influence of genetic polymorphisms on the effect of high and standard dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study. J Am Coll Cardiol 59:22 (2012), 1928–1937.
59. 59 Teng, R., Ticagrelor: pharmacokinetic, pharmacodynamic, and pharmacogenetic profile: an update. Clin Pharmacokinet 54:11 (2015), 1125–1138.
60. 60 Teng, R., Oliver, S., Hayes, M.A., et al. Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. Drug Metab Dispos 38:9 (2010), 1514–1521.
61. 61 Wallentin, L., Becker, R.C., Budaj, A., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361 (2009), 1045–1057.
62. 62 Storey, R.F., Melissa Thornton, S., Lawrance, R., et al. Ticagrelor yields consistent dose-dependent inhibition of ADP-induced platelet aggregation ni patients with atherosclerotic disease regardless of genotypic variations in P2RY12, P2RY1, and ITGB3. Platelets 20 (2009), 341–348.
63. 63 Tantry, U.S., Bliden, K.P., Wei, C., et al. First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies. Circ Cardiovasc Genet 3:6 (2010), 556–566.
64. 64 Akerblom, A., Eriksson, N., Wallentin, L., et al. Polymorphism of the cystatin C gene in patients with acute coronary syndromes: results from the Platelet Inhibition and Patient Outcomes Study. Am Heart J 168 (2014), 96–102.e2.
65. 65 Varenhorst, C.M.H., Eriksson, N., Johansson, Å., et al. Ticagrelor plasma levels but not clinical outcomes are associated with transporter and metabolism enzyme genetic polymorphisms. J Am Coll Cardiol, 63(12_S), 2014, A25.
66. 66 Sweezy, T., Mousa, S.A., Genotype-guided use of oral antithrombotic therapy: a pharmacoeconomic perspective. Personalized Medicine 11:2 (2014), 223–235.
67. 67 Peterson, J., Field, J., Unertl, K., et al. Physician response to implementation of genotype-tailored antiplatelet therapy. Clinical Pharmacology & Therapeutics, 2016 [Epub ahead of print].
68. 68 Fontana, P., Berdague, P., Castelli, C., et al. Clinical predictors of dual aspirin and clopidogrel poor responsiveness in stable cardiovascular patients from the ADRIE study. J Thromb Haemost 8 (2010), 2614–2623.
69. 69 Gremmel, T., Steiner, S., Seidinger, D., et al. Adenosine disphosphate-inducible platelet reactivity shows a pronounced age dependency in the initial phase of antiplatelet therapy with clopidogrel. J Thromb Haemost 8 (2010), 37–42.
70. 70 Tidjane, M.A., Voisin, S., Lhermusier, T., et al. More on: adenosine disphosphate-inducible platelet reactivity shows a pronounced age dependency in the initial phase of antiplatelet therapy with clopidogrel. J Thromb Haemost 9 (2011), 614–616.